Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-940-1 | CAS number: 112-15-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From October 23, 2020 to August 13, 2021
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 021
- Report date:
- 2021
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 2018-06-25
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- 2-(2-ethoxyethoxy)ethyl acetate
- EC Number:
- 203-940-1
- EC Name:
- 2-(2-ethoxyethoxy)ethyl acetate
- Cas Number:
- 112-15-2
- Molecular formula:
- C8H16O4
- IUPAC Name:
- 2-(2-ethoxyethoxy)ethyl acetate
- Test material form:
- liquid
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source of test material: Production lot
- Lot/batch number of test material: P230220120
- Expiration date of the lot/batch: 2023-04-29
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Cool, well ventilated place
- Stability under storage conditions: Stable
- Stability under test conditions: Stable
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Animal Breeding Facility, Jai Research Foundation
- Age at study initiation: 12 - 14 weeks
- Weight at study initiation: 198.9 - 249.1 g
- Fasting period before study: No
- Housing: Mated females individually caged in solid floor polypropylene rodent cages with stainless steel top grill
- Diet: Teklad certified global 14% protein rodent diet, ad libitum
- Water: Water cleaned and filtered by reverse osmosis, ad libitum
- Acclimation period: 8 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 24 deg C
- Humidity (%): 30 - 70%
- Air changes (per hr): > 15
- Photoperiod (hrs dark / hrs light): 12 / 12
IN-LIFE DATES: From: 2020-11-09 To: 2021-05-28
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
Daily, prior to dosing, and utilised within 4 hours of peparation
VEHICLE
- Justification for use and choice of vehicle: Water was used as the vehicle as the test item was readily miscible in that medium
- Concentration in vehicle: 0, 10, 50 and 100 mg/mL
- Amount of vehicle: Dose volume of 10 mL/kg body weight administered - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Active ingredient content and homogeneity of formulations were analysed once before initiation of treatment and once during the treatment period. Three aliquots (from the upper, middle and lower layers) from each of the dose formulations and one aliquot from the vehicle control were sampled. Analysis was by GC/FID. On each analytical occasion, the mean concentration was determined and compared with the nominal value. The acceptance criteria were ± 10% deviation from the nominal value and %CV < 10.
- Details on mating procedure:
- - Impregnation procedure: Cohoused
- M/F ratio per cage: 1/1
- Verification of same strain and source of both sexes: Yes
- Proof of pregnancy: Vaginal plug / sperm in vaginal smear referred to as day 0 of pregnancy
- Any other deviations from standard protocol: No - Duration of treatment / exposure:
- From Day 5 to Day 19 of gestation
- Frequency of treatment:
- Once daily
- Duration of test:
- 20 days
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- Vehicle control
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 500 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 25
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Based on outcome of a preliminary dose-ranging screen
- Rationale for animal assignment: Random
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice daily for mortality/morbidity
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Twice daily
BODY WEIGHT: Yes
- Time schedule for examinations: Gestation days 0, 3, 5, 8, 11, 14, 17 and 20
FOOD CONSUMPTION AND COMPOUND INTAK: Yes
- Time schedule for examinations: Gestation days 0, 3, 5, 8, 11, 14, 17 and 20
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes for periods - gestation days 0-3, 3-5, 5-8, 8-11, 11-14, 14-17 and 17-20
WATER CONSUMPTION AND COMPOUND INTAKE: No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: Those with macroscopic abnormalities and the ovaries, uterus and cervix from all animals. Thyroid weight determined and the tissue preserved for possible histopathology.
OTHER:
At the time of terminal sacrifice on Day 20 of gestation, blood samples were taken from all surviving dams for thyroid hormone analysis. Serum thyroid hormones T3 and T4 were analysed using bioanalytical methods and TSH was analysed using an ELISA method. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes: half per litter
- Skeletal examinations: Yes: half per litter
- Head examinations: Yes: half per litter - Statistics:
- Parametric data (body weight, body weight gain/change, food consumption, organ weight, and prenatal data etc.) was subjected to Shapiro-Wilk’s test for normality check wherever applicable, followed by Bartlett’s test to meet the homogeneity of variance before conducting Analysis of Variance (ANOVA) and Dunnett’s t-test. If the data did not meet the normality, data were transformed to check the normality again. If transformed data did not meet the normality check, the Kruskal-wallis/Mann Whitney test was performed to calculate significance. If the data did not meet the homogeneity of variance, statistical analysis was extended following the decision tree of Gad (Gad, S.C., 2007). Non-parametric data (mortality rate, pregnancy rate, foetal observations etc.) were analysed using Chi-square test.
Count data (foetal count, number of corpora lutea, number of implants, number of live foetuses, number of dead foetuses, number of pre-implantation loss, number of post-implantation loss, number of resorptions) were be subjected to non-parametric Kruskal-Wallis test.
AGD was normalised (the ratio of AGD to the cube root of body weight) and then subjected to statistical analysis. - Indices:
- Number of male foetuses
Number of female foetuses
Body weight of male foetuses (g)
Body weight of female foetuses (g)
Foetus sex (based on ano-genital distance)
Ano-genital distance (mm)
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No clinical sign of toxicity was observed.
- Mortality:
- no mortality observed
- Description (incidence):
- No mortality and morbidity were observed.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- The mean body weight and corrected body weight of the pregnant female rats were comparable between the control and treated groups up to a dose level of 500 mg/kg/day. At 1000 mg/kg/day, a statistically significant decrease in the mean body weight of the pregnant female rats was observed on gestation days 17 and 20. A decreased mean body weight for this group was also observed during gestation days 11 and 14 without statistical significance. A statistically significant decrease in day 20 corrected body weight was also noted for this group.
The mean body weight change of pregnant female rats was comparable between the control and test treated groups up to a dose level of 500 mg/kg/day. At 1000 mg/kg/day, a statistically significant decrease in mean body weight change was observed during gestation days 5-20.
Decreases in the mean body weight and body weight change are correlated with decreased mean food consumption and are considered as adverse effect of treatment. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Mean food consumption of the pregnant female rats was comparable between the control and treated groups up to a dose level of 500 mg/kg/day. A statistically significant reduced mean food consumption was seen in 1000 mg/kg/day treated rats over gestation days 5-8, 11-14, and 5-20.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- Treatment did not lead to any alteration in absolute and relative weights of the thyroid gland.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- External and internal (gross) examination of terminally sacrificed female rats did not reveal any lesion of pathological significance.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- Histological examination of the thyroid gland did not reveal any lesion in rats of the control as well as the high dose groups except ultimobranchial cyst/s present in a single female rat of the control group, which was considered as spontaneous or incidental in nature
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Thyroid Hormone Analysis
Serum TSH level was comparable with that of the control group. Statistically significant lower serum levels of T3 and T4 were observed in pregnant female rats belonging to 100 mg/kg/day dose group. Statistically significant lower serum level of T4 was also observed in pregnant female rats belonging to 1000 mg/kg/day dose group. These effects are considered as incidental and unrelated to the test item treatment due to lack of dose-dependency and absence of other supporting findings (Serum TSH level and other thyroid-related parameters such as thyroid weight and thyroid histopathology were comparable with that of the control group)
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- no effects observed
- Details on maternal toxic effects:
- The mean absolute and relative uterine weight of the pregnant female rats were comparable between the control and the test item treated groups.
The mean numbers of corpora lutea, implantation sites, live foetuses, dead foetuses, resorptions (early, late, and total), pre-implantation loss, and post-implantation loss, the mean percent of live foetuses, dead foetuses, pre-implantation loss, post-implantation loss, and total resorptions were comparable between the control, and test item treated groups.
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 500 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- Dose descriptor:
- LOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
Maternal abnormalities
- Abnormalities:
- no effects observed
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- The mean body weight of male, female and total foetuses (male + female) was comparable between the control and treated groups
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- no effects observed
- External malformations:
- no effects observed
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Incidences of skeletal malformations were not observed in any of the dose groups.
Skeletal variations were noted as follows: A statistically significant decrease in the number of foetuses with 14th rib: extra ossification centre was observed in the 100 and 1000 mg/kg/day dose groups. This finding was a result of higher number of incidences in controls compared to treatment groups and has no toxicological relevance. A statistically significant increase in the number of foetuses with 2nd sternebrae: unossified was observed in the 500 mg/kg/day dose group. Due to the lack of dose dependency, this increase was considered as incidental and non-adverse. A statistically significant increase in the number of foetuses with xiphisternum: unossified was observed in the 500 mg/kg/day dose group. A statistically significant increase in the number of foetuses and litters with xiphisternum: unossified was observed in the 1000 mg/kg/day dose group. The increase in number of foetuses and litters with xiphisternum: unossified indicate a delayed ossification associated with marginal reduced foetal weights i.e., a delay in foetal development secondary to the maternal toxicity observed at this dose level rather than a direct effect on bone tissue. In addition, this increase in the number of foetuses and litters with Xiphisternum: Unossified was within the range of historical control data and therefore considered as a non-adverse effect of treatment. - Visceral malformations:
- no effects observed
- Description (incidence and severity):
- No treatment-related visceral anomalies were observed in foetuses of the treatment groups up to the dose level of 1000 mg/kg/day. Some spontaneous findings such as situs inversus (one foetus from the 500 mg/kg/day dose group) and dilated ureter (two foetuses from the control and one foetus from the 500 mg/kg/day dose group) were observed.
- Other effects:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Anogenital distance (AGD)
The mean anogenital distance of female foetuses was comparable between the control and treated groups.
A statistically significant increase in AGD of male foetuses was observed in the 1000 mg/kg bw/day dose group. However, due to absence of an observed effect in female foetuses and considering that the mean value of AGD of treated male foetuses is only 1.67% higher than that of controls, the finding was considered non-adverse (Robert, H. G., Jr. Joseph, F. H., Donald, G. S., John, F. K., Vincent, L. R., 1999: “Interpreting the Toxicologic Significance of Alterations in Anogenital Distance: Potential for Confounding Effects of Progeny Body Weights”, Reproductive Toxicology, 13: 383-390).
Effect levels (fetuses)
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Lack of effects
Fetal abnormalities
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Developmental effects observed:
- no
Any other information on results incl. tables
Maternal Data
Dose level |
0 mg/kg bw/day |
100 mg/kg bw/day |
500 mg/kg bw/day |
1000 mg/kg bw/day |
||||
Parameters |
N |
% |
N |
% |
N |
% |
N |
% |
N° of estrus positive rats |
25 |
100.00 |
25 |
100.00 |
25 |
100.00 |
25 |
100.00 |
N° of discarded after copulation |
0 |
0.00 |
0 |
0.00 |
0 |
0.00 |
0 |
0.00 |
N° with premature delivery/abortion |
0 |
0.00 |
0 |
0.00 |
0 |
0.00 |
0 |
0.00 |
Mortality |
0 |
0.00 |
0 |
0.00 |
0 |
0.00 |
0 |
0.00 |
N° sacrificed under moribund condition |
0 |
0.00 |
0 |
0.00 |
0 |
0.00 |
0 |
0.00 |
N° sacrificed at term (at 20thday of Gestation) |
25 |
100.00 |
25 |
100.00 |
25 |
100.00 |
25 |
100.00 |
N° non-pregnant females |
1 |
4.00 |
0 |
0.00 |
4 |
16.00 |
0 |
0.00 |
N° pregnant females |
24 |
96.00 |
25 |
100.00 |
21 |
84.00 |
25 |
100.00 |
N° with at least one viable foetus |
24 |
96.00 |
25 |
100.00 |
21 |
84.00 |
25 |
100.00 |
N° with all fetuses viable |
23 |
95.83 |
22 |
88.00 |
17 |
80.95 |
20 |
80.00 |
N° with at least one dead foetus |
0 |
0.00 |
0 |
0.00 |
0 |
0.00 |
0 |
0.00 |
N° with all dead foetuses |
0 |
0.00 |
0 |
0.00 |
0 |
0.00 |
0 |
0.00 |
N° with resorption |
1 |
4.17 |
3 |
12.00 |
4 |
19.05 |
5 |
20.00 |
N° with complete resorption |
0 |
0.00 |
0 |
0.00 |
0 |
0.00 |
0 |
0.00 |
Key: N = Number of observations
Maternal Body Weight (g)
Dose level |
0 mg/kg bw/day |
100 mg/kg bw/day |
500 mg/kg bw/day |
1000 mg/kg bw/day |
||||||||
Gestation Day |
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
0 |
238.72 |
9.11 |
24 |
239.33 |
10.39 |
25 |
238.73 |
9.73 |
21 |
237.59 |
9.01 |
25 |
3 |
247.55 |
10.03 |
24 |
246.33 |
10.49 |
25 |
246.45 |
9.28 |
21 |
246.08 |
8.17 |
25 |
5 |
253.22 |
10.42 |
24 |
252.37 |
10.22 |
25 |
251.79 |
9.47 |
21 |
251.08 |
9.06 |
25 |
8 |
259.48 |
10.98 |
24 |
259.21 |
11.18 |
25 |
258.14 |
9.91 |
21 |
255.46 |
8.94 |
25 |
11 |
271.94 |
11.25 |
24 |
271.46 |
11.31 |
25 |
268.92 |
10.41 |
21 |
265.73 |
10.11 |
25 |
14 |
284.36 |
11.38 |
24 |
284.87 |
12.15 |
25 |
281.01 |
10.72 |
21 |
276.54 |
10.94 |
25 |
17 |
308.40 |
12.67 |
24 |
307.61 |
13.93 |
25 |
302.82 |
13.39 |
21 |
296.08 *€ |
16.54 |
25 |
20 |
334.20 |
12.27 |
24 |
335.38 |
14.88 |
25 |
329.56 |
14.82 |
21 |
320.06**€ |
20.76 |
25 |
20thday Corrected Body Weight (g) |
271.44 |
11.85 |
24 |
272.37 |
12.65 |
25 |
270.70 |
12.48 |
21 |
261.48 *€ |
14.74 |
25 |
Key: N = Number of observations
SD = Standard deviation
*= significantly lower than control (p<0.05)
**= significantly lower than control (p<0.01)
€ =Dunnett's test with Bonferroni adjustment
Note: Values of non-pregnant female rats were not used for statistical analysis.
Maternal Body Weight Change (%)
Dose level |
0 mg/kg bw/day |
100 mg/kg bw/day |
500 mg/kg bw/day |
1000 mg/kg bw/day |
||||||||
Gestation Period |
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
0-3 |
3.70 |
1.11 |
24 |
2.94 |
1.38 |
25 |
3.25 |
1.45 |
21 |
3.61 |
1.70 |
25 |
3-5 |
2.29 |
1.13 |
24 |
2.47 |
0.93 |
25 |
2.17 |
0.64 |
21 |
2.03 |
1.07 |
25 |
5-8 |
2.47 |
1.06 |
24 |
2.70 |
1.12 |
25 |
2.52 |
0.81 |
21 |
1.75 |
1.08 |
25 |
8-11 |
4.81 |
1.27 |
24 |
4.74 |
1.33 |
25 |
4.18 |
1.00 |
21 |
4.02 |
1.17 |
25 |
11-14 |
4.58 |
1.18 |
24 |
4.94 |
1.01 |
25 |
4.50 |
1.00 |
21 |
4.07 |
1.17 |
25 |
14-17 |
8.46 |
1.22 |
24 |
7.98 |
1.18 |
25 |
7.75 |
1.64 |
21 |
7.03 |
3.24 |
25 |
17-20 |
8.40 |
2.10 |
24 |
9.05 |
2.16 |
25 |
8.84 |
1.81 |
21 |
8.07 |
2.78 |
25 |
5-20 |
32.04 |
3.16 |
24 |
32.92 |
3.58 |
25 |
30.91 |
4.06 |
21 |
27.39**€ |
5.18 |
25 |
Key: N = Number of observations
SD = Standard deviation
**= significantly lower than control (p<0.01)
€ =Dunnett's test with Bonferroni adjustment
Note: Values of non-pregnant female rats were not used for statistical analysis.
Food Consumption (g/day)
Dose level |
0 mg/kg bw/day |
100 mg/kg bw/day |
500 mg/kg bw/day |
1000 mg/kg bw/day |
||||||||
Gestation Period |
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
0-3 |
18.71 |
1.94 |
24 |
18.44 |
2.13 |
25 |
18.08 |
2.53 |
21 |
18.89 |
2.34 |
25 |
3-5 |
20.88 |
2.71 |
24 |
20.92 |
2.68 |
25 |
20.36 |
2.37 |
21 |
21.24 |
2.09 |
25 |
5-8 |
20.68 |
2.27 |
24 |
20.78 |
2.75 |
25 |
20.20 |
2.32 |
21 |
18.93 *€ |
2.53 |
25 |
8-11 |
21.28 |
2.30 |
24 |
21.86 |
1.69 |
25 |
20.34 |
2.73 |
21 |
19.75 |
2.15 |
25 |
11-14 |
23.56 |
1.46 |
24 |
24.34 |
2.45 |
25 |
22.48 |
2.24 |
21 |
21.98 *€ |
2.20 |
25 |
14-17 |
23.50 |
2.23 |
24 |
23.97 |
2.69 |
25 |
22.11 |
2.02 |
21 |
21.87 |
2.99 |
25 |
17-20 |
22.48 |
2.30 |
24 |
23.60 |
3.28 |
25 |
21.99 |
2.73 |
21 |
21.48 |
3.09 |
25 |
5-20 |
22.30 |
1.02 |
24 |
22.90 |
1.88 |
25 |
21.42 |
1.80 |
21 |
20.80 **€ |
1.80 |
25 |
Key: N = Number of observations
SD = Standard deviation
*= significantly lower than control (p<0.05)
**= significantly lower than control (p<0.01)
€ =Dunnett's test with Bonferroni adjustment
Note: Values of non-pregnant female rats were not used for statistical analysis.
Prenatal Data
Dose level |
0 mg/kg bw/day |
100 mg/kg bw/day |
500 mg/kg bw/day |
1000 mg/kg bw/day |
||||||||
Parameter |
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
Absolute Uterus Weight (g) |
62.75 |
8.52 |
24 |
63.00 |
5.75 |
25 |
58.85 |
13.60 |
21 |
58.57 |
13.50 |
25 |
Relative Uterus Weight (%) |
18.77 |
2.41 |
24 |
18.78 |
1.44 |
25 |
17.78 |
3.75 |
21 |
18.18 |
3.73 |
25 |
Noof CL |
13.50 |
1.44 |
24 |
13.12 |
1.56 |
25 |
13.38 |
1.40 |
21 |
13.28 |
1.86 |
25 |
N° of Implants |
11.96 |
1.76 |
24 |
12.00 |
1.04 |
25 |
11.57 |
2.71 |
21 |
11.64 |
2.71 |
25 |
Noof Live Foetus |
11.92 |
1.72 |
24 |
11.84 |
0.99 |
25 |
11.19 |
2.93 |
21 |
11.40 |
2.84 |
25 |
Noof Dead Foetus |
0.00 |
0.00 |
24 |
0.00 |
0.00 |
25 |
0.00 |
0.00 |
21 |
0.00 |
0.00 |
25 |
N° of Early Resorption |
0.04 |
0.20 |
24 |
0.12 |
0.33 |
25 |
0.24 |
0.54 |
21 |
0.16 |
0.37 |
25 |
N° of Late Resorption |
0.00 |
0.00 |
24 |
0.04 |
0.20 |
25 |
0.14 |
0.48 |
21 |
0.08 |
0.28 |
25 |
N° of Total Resorption |
0.04 |
0.20 |
24 |
0.16 |
0.47 |
25 |
0.38 |
0.92 |
21 |
0.24 |
0.52 |
25 |
N° of Pre-Implant Loss |
1.54 |
1.67 |
24 |
1.12 |
1.45 |
25 |
1.81 |
2.23 |
21 |
1.64 |
2.18 |
25 |
N° of Post Implant Loss |
0.04 |
0.20 |
24 |
0.16 |
0.47 |
25 |
0.38 |
0.92 |
21 |
0.24 |
0.52 |
25 |
Pre-Implant Loss (%) |
11.06 |
11.97 |
24 |
7.73 |
9.62 |
25 |
13.83 |
18.77 |
21 |
12.47 |
16.18 |
25 |
Post Implant Loss (%) |
0.30 |
1.46 |
24 |
1.24 |
3.58 |
25 |
3.53 |
8.78 |
21 |
2.79 |
8.24 |
25 |
Live Foetus (%) |
99.70 |
1.46 |
24 |
98.76 |
3.58 |
25 |
96.47 |
8.78 |
21 |
97.21 |
8.24 |
25 |
Dead Foetus (% ) |
0.00 |
0.00 |
24 |
0.00 |
0.00 |
25 |
0.00 |
0.00 |
21 |
0.00 |
0.00 |
25 |
Total Resorption (%) |
0.30 |
1.46 |
24 |
1.24 |
3.58 |
25 |
3.53 |
8.78 |
21 |
2.79 |
8.24 |
25 |
Key: N = Number of observations
SD = Standard deviation
CL = Corpora lutea
Note:Values of non-pregnant female rats were not used for statistical analysis
Foetal Data
Dose level |
0 mg/kg b. wt./day |
100 mg/kg b. wt./day |
500 mg/kg b. wt./day |
1000 mg/kg b. wt./day |
||||||||
Parameter |
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
N° of Male Foetus |
5.83 |
2.18 |
24 |
5.80 |
2.10 |
25 |
5.52 |
2.64 |
21 |
5.44 |
1.92 |
25 |
N° of Female Foetus |
6.08 |
2.41 |
24 |
6.04 |
1.84 |
25 |
5.67 |
2.61 |
21 |
6.21 |
1.93 |
24 |
Total Foetus (Male + Female) |
11.92 |
1.72 |
24 |
11.84 |
0.99 |
25 |
11.19 |
2.93 |
21 |
11.40 |
2.84 |
25 |
Male Foetus Weight (g) |
3.52 |
0.21 |
24 |
3.54 |
0.23 |
25 |
3.46 |
0.24 |
21 |
3.41 |
0.37 |
25 |
Female Foetus Weight (g) |
3.32 |
0.22 |
24 |
3.31 |
0.20 |
25 |
3.28 |
0.25 |
21 |
3.25 |
0.37 |
24 |
Total Foetus Weight (Male + Female) |
3.42 |
0.21 |
24 |
3.43 |
0.20 |
25 |
3.36 |
0.24 |
21 |
3.33 |
0.36 |
25 |
AGD – Male |
1.80 |
0.02 |
24 |
1.80 |
0.02 |
25 |
1.81 |
0.02 |
21 |
1.83*Φ |
0.05 |
25 |
AGD – Female |
0.89 |
0.01 |
24 |
0.89 |
0.03 |
25 |
0.89 |
0.01 |
21 |
0.90 |
0.02 |
24 |
Male Sex Ratio (%) |
49.43 |
18.30 |
24 |
48.63 |
16.23 |
25 |
49.59 |
19.14 |
21 |
49.54 |
17.59 |
25 |
Key: N = Number of observations
SD = Standard deviation
M = Male Foetus
F = Female
AGD = Anogenital Distance
* = Significantly higher than control (p<0.05)
Φ =Cochran's t test
Foetal Gross External Observations
Dose level |
0 mg/kg bw/day |
100 mg/kg bw/day |
500 mg/kg bw/day |
1000 mg/kg bw/day |
||||||||
N° of Foetuses (Litter) Examined |
286 (24) |
296 (25) |
235 (21) |
285 (25) |
||||||||
A |
B |
C |
A |
B |
C |
A |
B |
C |
A |
B |
C |
|
Observation: |
|
|||||||||||
Abnormality detected |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
Key: A= Number of foetus affected
B = Number of litter affected
C = % Incidence of litter
Foetal Visceral Observations
Dose level |
0 mg/kg bw/day |
100 mg/kg bw/day |
500 mg/kg bw/day |
1000 mg/kg bw/day |
||||||||
N° of Foetuses (Litters) Examined |
135 (24) |
144 (25) |
115 (21) |
137 (25) |
||||||||
A |
B |
C |
A |
B |
C |
A |
B |
C |
A |
B |
C |
|
Observation: |
|
|||||||||||
Ureter: Dilated |
2 |
2 |
8.33 |
0 |
0 |
0.00 |
1 |
1 |
4.76 |
0 |
0 |
0.00 |
Situs inversus |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
1 |
1 |
4.76 |
0 |
0 |
0.00 |
Key: A = Number of foetus affected
B = Number of litter affected
C = % Incidence of litter
Foetal Head Razor Section Observations
Dose level |
0 mg/kg bw/day |
100 mg/kg bw/day |
500 mg/kg bw/day |
1000 mg/kg bw/day |
||||||||
N° of Foetuses (Litters) Examined |
135 (24) |
144 (25) |
115 (21) |
137 (25) |
||||||||
A |
B |
C |
A |
B |
C |
A |
B |
C |
A |
B |
C |
|
Observation: |
|
|||||||||||
Abnormality detected |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
Key: A= Number of foetus affected
B = Number of litter affected
C = % Incidence of litter
Foetal Skeletal Observations
Dose level |
0 mg/kg bw/day |
100 mg/kg bw/day |
500 mg/kg bw/day |
1000 mg/kg bw/day |
||||||||||||||||||
N° of Foetuses (Litters) Examined |
151 (24) |
152 (25) |
120 (21) |
148 (25) |
||||||||||||||||||
A |
B |
C |
A |
B |
C |
A |
B |
C |
A |
B |
C |
|||||||||||
Observation$: |
|
|||||||||||||||||||||
11thThoracic centrum:Dumbbell ossification |
2 |
2 |
8.33 |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
||||||||||
14thRib:Extra ossification centre |
26 |
14 |
58.33 |
9#* |
9 |
36.00 |
18 |
8 |
38.10 |
13#* |
9 |
36.00 |
||||||||||
1stSternebrae:Unossified |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
2 |
1 |
4.76 |
0 |
0 |
0.00 |
||||||||||
2ndSternebrae:Incomplete ossification |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
1 |
1 |
4.76 |
0 |
0 |
0.00 |
||||||||||
2ndSternebrae:Unossified |
0 |
0 |
0.00 |
3 |
2 |
8.00 |
7#* |
2 |
9.52 |
3 |
3 |
12.00 |
||||||||||
3rdSternebrae:Bipartite ossification |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
1 |
1 |
4.00 |
||||||||||
3rdSternebrae:Unossified |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
2 |
1 |
4.76 |
0 |
0 |
0.00 |
||||||||||
3rdSternebrae:Misshapen |
1 |
1 |
4.17 |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
1 |
1 |
4.00 |
||||||||||
3rdSternebrae: |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
1 |
1 |
4.00 |
||||||||||
4thSternebrae:Bipartite ossification |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
1 |
1 |
4.00 |
||||||||||
4thSternebrae:Unossified |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
2 |
1 |
4.76 |
0 |
0 |
0.00 |
||||||||||
4thSternebrae:Misshapen |
1 |
1 |
4.17 |
1 |
1 |
4.00 |
0 |
0 |
0.00 |
2 |
2 |
8.00 |
||||||||||
5thSternebrae:Dumbbell ossification |
1 |
1 |
4.17 |
1 |
1 |
4.00 |
1 |
1 |
4.76 |
1 |
1 |
4.00 |
||||||||||
5thSternebrae:Incomplete ossification |
7 |
6 |
25.00 |
3 |
3 |
12.00 |
2 |
2 |
9.52 |
1 |
1 |
4.00 |
||||||||||
5thSternebrae:Unossified |
14 |
9 |
37.50 |
10 |
7 |
28.00 |
10 |
5 |
23.81 |
13 |
10 |
40.00 |
||||||||||
Caudal centrum:Unossified |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
2 |
1 |
4.76 |
0 |
0 |
0.00 |
||||||||||
Interparietal:Incomplete ossification |
7 |
4 |
16.67 |
3 |
2 |
8.00 |
5 |
4 |
19.05 |
4 |
4 |
16.00 |
||||||||||
Occipital:Bipartite ossification |
0 |
0 |
0.00 |
1 |
1 |
4.00 |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
||||||||||
Occipital:Incomplete ossification |
1 |
1 |
4.17 |
0 |
0 |
0.00 |
3 |
2 |
9.52 |
0 |
0 |
0.00 |
||||||||||
Parietal: Incomplete ossification |
2 |
2 |
8.33 |
1 |
1 |
4.00 |
2 |
1 |
4.76 |
0 |
0 |
0.00 |
||||||||||
Pubic: Unossified |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
2 |
1 |
4.76 |
0 |
0 |
0.00 |
||||||||||
Rib: Full supernumerary |
2 |
2 |
8.33 |
1 |
1 |
4.00 |
3 |
3 |
14.29 |
1 |
1 |
4.00 |
||||||||||
Rib: Short supernumerary |
12 |
8 |
33.33 |
11 |
7 |
28.00 |
12 |
10 |
47.62 |
12 |
8 |
32.00 |
||||||||||
Sacral centrum: Unossified |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
1 |
1 |
4.76 |
0 |
0 |
0.00 |
||||||||||
Sacral vertebra: Unossified |
0 |
0 |
0.00 |
0 |
0 |
0.00 |
1 |
1 |
4.76 |
0 |
0 |
0.00 |
||||||||||
Squamosal: Incomplete ossification |
1 |
1 |
4.17 |
0 |
0 |
0.00 |
2 |
1 |
4.76 |
0 |
0 |
0.00 |
||||||||||
Xiphisternum: Incomplete ossification |
12 |
5 |
20.83 |
11 |
7 |
28.00 |
14 |
9 |
42.86 |
17 |
9 |
36.00 |
||||||||||
Xiphisternum: Unossified |
1 |
1 |
4.17 |
2 |
2 |
8.00 |
6#* |
4 |
19.05 |
18#* |
11#* |
44.00 |
||||||||||
Key: $ = One Foetus may have more than one Observation
* = Chi-square test
A = Number of foetus affected
B = Number of litter affected
C = % Incidence of litter
#= Significantly different than control (p<0.05)
Terminal Body Weight and Thyroid Weight
Parameters |
Treament |
|||||||||||
0 mg/kg bw/day |
100 mg/kg bw/day |
500 mg/kg bw/day |
1000 mg/kg bw/day |
|||||||||
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
|
B. wt. -TS (g) |
334.2000 |
12.2736 |
24 |
335.3760 |
14.8779 |
25 |
329.5571 |
14.8163 |
21 |
320.0600**€ |
20.7559 |
25 |
Absolute Organ Weight |
||||||||||||
Thyroid gland (g) |
0.0150 |
0.0025 |
24 |
0.0149 |
0.0026 |
25 |
0.0156 |
0.0023 |
21 |
0.0145 |
0.0023 |
25 |
Relative Organ Weight |
||||||||||||
Thyroid gland (%) |
0.0045 |
0.0007 |
24 |
0.0044 |
0.0007 |
25 |
0.0047 |
0.0007 |
21 |
0.0045 |
0.0008 |
25 |
Key: € =Dunnett’s t test with Bonferroni adjustment
**= 1%
Gross and Microscopic Findings
Treatment |
0 mg/kg bw/day |
100 mg/kg bw/day |
500 mg/kg bw/day |
1000 mg/kg bw/day |
|
Organs & Lesions |
Sex |
F |
F |
F |
F |
N° of Animals |
25 |
25 |
25 |
25 |
|
GROSS FINDINGS |
|||||
External |
|||||
No abnormality detected |
25 |
25 |
25 |
25 |
|
Internal |
|||||
No abnormality detected |
25 |
25 |
25 |
25 |
|
MICROSCOPIC FINDINGS |
N° of Dams for Summary of Microscopic Finding |
||||
24* |
25 |
25 |
25 |
||
Thyroid glands |
|||||
Ultimobranchial cyst |
1 |
X |
X |
0 |
Key: ‘X’ = Organs not examined
* = Non pregnant dam was not considered for summary of histopathological evaluation.
Thyroid hormone analysis
Treatment |
Mean |
SD |
N |
TSH (ng/mL) |
|||
0mg/kg bw/day |
0.862 |
0.274 |
24 |
100mg/kg bw/day |
0.814 |
0.299 |
25 |
500mg/kg bw/day |
1.021 |
0.421 |
21 |
1000mg/kg bw/day |
0.828 |
0.265 |
25 |
T3 (ng/L) |
|||
0mg/kg bw/day |
0.240 |
0.059 |
24 |
100mg/kg bw/day |
0.206*Φ |
0.036 |
25 |
500mg/kg bw/day |
0.233 |
0.031 |
21 |
1000mg/kg bw/day |
0.232 |
0.030 |
25 |
T4 (ng/L) |
|||
0mg/kg bw/day |
27.626 |
7.794 |
24 |
100mg/kg bw/day |
22.347**Φ |
4.108 |
25 |
500mg/kg bw/day |
24.271 |
3.925 |
21 |
1000mg/kg bw/day |
22.834*Φ |
4.771 |
25 |
Key: N = Number of observations
SD = Standard deviation
Φ=Cochran's t test
**= Significantly lower than control (p<0.01)
* = Significantly lower than control (p<0.05)
Applicant's summary and conclusion
- Conclusions:
- The No Observed Adverse Effect Level (NOAEL) is 500 mg/kg bw/day for maternal toxicity and 1000 mg/kg bw/day for foetal toxicity. The LOAEL for maternal toxicity was 1000 mg/kg/day based on adverse effects observed on body weight, body weight change, and food consumption.
- Executive summary:
Potential developmental toxicity has been investigated in the rat in a GLP compliant study conducted according to OECD TG 414. The No Observed Adverse Effect Level (NOAEL) was 500 mg/kg bw/day for maternal toxicity and 1000 mg/kg bw/day for foetal toxicity. The LOAEL for maternal toxicity was 1000 mg/kg/day based on adverse effects observed on body weight, body weight change, and food consumption.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)